Animal-Health Archives

Humans, animals and the environment - our health is all connected

Why the One Health approach is important now more than ever

April 15, 2024

Merck Animal Health Completes Acquisition of Elanco’s Aqua Business

Acquisition delivers industry-leading portfolio, scientific and research capabilities, for enhanced customer benefits RAHWAY, N.J., July 9, 2024 – Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced the completion of its acquisition of the aqua business of Elanco Animal Health Incorporated (NYSE: ELAN). The completion of this acquisition bolsters Merck Animal Health’s position in the aqua industry with a comprehensive approach to promote fish health, welfare and sustainability in aquaculture, conservation, and fisheries. “With the completion of this acquisition, we are well positioned within the aquaculture industry with a robust and comprehensive portfolio across warm water, cold water, vaccines, anti-parasitic treatments, water supplements and nutrition,” said Rick DeLuca, president, Merck Animal Health. “We are excited to welcome our new colleagues to Merck

July 9, 2024

USDA Approves Merck Animal Health’s NOBIVAC® NXT Canine Flu H3N2 – The First and Only RNA-Particle Technology Vaccine for Canine Influenza

Innovative technology represents a breakthrough scientific achievement for highly contagious respiratory disease RAHWAY, N.J., June 25, 2024 – Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), announced today the U.S. Department of Agriculture (USDA) approval of NOBIVAC ® NXT Canine Flu H3N2, a next-level solution to help safeguard dogs against the ongoing threat of canine influenza. The product is expected to be available at veterinary clinics and hospitals nationwide late this summer. Merck Animal Health has a long-standing commitment to discovering and developing innovative preventive medicines that support veterinary healthcare teams and improve the lives of pets. NOBIVAC NXT is a revolutionary, first-of-its-kind vaccine technology for companion animals that leverages RNA-particle technology, allowing for a precise immune response to protect against a wide range of viral and

June 25, 2024

Merck Animal Health to Acquire Elanco’s Aqua Business

Bolsters Merck Animal Health’s position in the aqua industry with comprehensive approach to ensure fish health, welfare and sustainability in aquaculture, conservation and fisheries Complements Merck Animal Health’s broad portfolio of veterinary pharmaceuticals, vaccines and technology solutions Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that it has signed a definitive agreement to acquire the aqua business of Elanco Animal Health Incorporated (NYSE: ELAN) for $1.3 billion in cash, consisting of an innovative portfolio of medicines and vaccines, nutritionals and supplements for aquatic species; two related aqua manufacturing facilities in Canada and Vietnam; as well as a research facility in Chile. The acquisition is expected to be completed by mid-year 2024, subject to approvals from regulatory authorities and other customary closing conditions. Upon

February 5, 2024

Merck Animal Health Supports Rabies Elimination by 2030 on World Rabies Day

Campaign raises awareness about importance of dog vaccination In recognition of World Rabies Day on September 28, Merck Animal Health, known as MSD Animal Health outside the United States and Canada, a division of Merck & Co., Inc., Kenilworth, N.J., USA (NYSE:MRK), today announced the launch of a global campaign to raise awareness among veterinarians, dog owners and volunteers who are committed to eliminate rabies through ongoing dog vaccination efforts. In partnership with Mission Rabies and Rabies Free Africa, the social media initiative recognizes and celebrates those individuals who are committed to protecting and saving canine as well as human lives, using the hashtag, #ForThemForUs. “Many of us love and rely on our dogs, who in many cases are not only much-loved family members, but also hard-working companions,” said Luke Gamble, BVSc, DVM&S, FRCVS, founder, Mission Rabies. “On this World Rabies Day, we want to recognize the invaluable role dogs play in our lives. When

September 28, 2020

Merck Animal Health Completes Acquisition of IdentiGEN

Strategic Transaction Enhances Farm-to-Table Animal Traceability Solutions for Livestock and Aquaculture Merck Animal Health, known as MSD Animal Health outside the United States and Canada, a division of Merck & Co., Inc., Kenilworth, N.J., USA (NYSE:MRK), today announced the completion of its acquisition of IdentiGEN, a leader in DNA-based animal traceability solutions for Livestock and Aquaculture from MML Growth Capital Partners Ireland. Specific terms of the agreement were not disclosed. IdentiGEN’s technology combines each species’ unique DNA (deoxyribonucleic acid) and data analytics to provide an evidence-based animal traceability solution, called DNA TraceBack®, to accurately and precisely trace beef, seafood, pork and poultry that is verifiable from farm-to-table. Food producers, processors and retailers are looking for accurate and complete animal traceability solutions that provide full accountability, as well as greater transparency, quality and sustainability of food

August 5, 2020

Merck Animal Health Completes Acquisition of Worldwide Rights to VECOXAN® Brand of Parasiticides for Ruminant Portfolio

Broadens Merck Animal Health’s Position with Enhanced Parasite Protection in Calves and Lambs Merck Animal Health, known as MSD Animal Health outside the United States and Canada, a division of Merck & Co., Inc., Kenilworth, N.J., USA (NYSE:MRK), today announced the completion of its previously announced acquisition of the worldwide rights to VECOXAN® (diclazuril), an oral suspension for the prevention of coccidiosis in calves and lambs, from Elanco Animal Health. VECOXAN is efficacious, in lambs, against the prevention of coccidiosis caused by Eimeria crandallis and Eimeria ovinoidalis , and in calves, against coccidiosis caused by Eimeria bovis and Eimeria zuernii. VECOXAN is available in Europe, South Africa, South Korea and Japan. Parasite control and protection is an essential and significant part of ruminant overall health management and outcomes. “With advanced digital and diagnostic solutions to manage the welfare of animals as critical components of our technology, we are

August 3, 2020

Merck Animal Health Receives U.S. FDA Approval of BRAVECTO® (fluralaner) Monthly Chews

Portfolio Expansion Ensures Dogs and Puppies 8 Weeks of Age and Older Receive Early, Broad-Spectrum Protection Against Fleas and Ticks Merck Animal Health, known as MSD Animal Health outside the United States and Canada, a division of Merck & Co., Inc., Kenilworth, N.J., USA, [NYSE: MRK], today announced the U.S. Food and Drug Administration’s approval of BRAVECTO ® 1-MONTH (fluralaner) Chews for dogs and puppies 8 weeks of age and older. The product is administered as a single, monthly flavored chew formulation for treatment and prevention of fleas and treatment and control of ticks. BRAVECTO 1-MONTH is expected to be available in the coming months. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200709005926/en/ Merck Animal Health Receives U.S. FDA Approval of BRAVECTO® (fluralaner) Monthly Chews (Photo: Business Wire) BRAVECTO 1-MONTH is an important addition to the company’s parasiticide portfolio, which are

July 9, 2020

Merck Animal Health Completes Acquisition of U.S. Rights to SENTINEL® Brand of Combination Parasiticides for Companion Animals

Further Solidifies Merck Animal Health’s Position in the U.S. Companion Animal Category with Comprehensive, Continuous Parasite Protection Complements Merck Animal Health’s Broad Portfolio of Vaccines and Pharmaceuticals Merck Animal Health, known as MSD Animal Health outside the United States and Canada, a division of Merck & Co., Inc., Kenilworth, N.J., USA (NYSE:MRK), today announced the completion of its previously announced acquisition of the U.S. rights to SENTINEL® FLAVOR TABS® and SENTINEL® SPECTRUM® Chews in the Companion Animal category from Virbac (NYSE Euronext:VIRP). Comprehensive parasite protection is an essential part of canine overall health and well-being. “Our veterinary medicines, including parasiticides, and vaccines continue to transform the animal health industry and further solidify our position in the U.S. Companion Animal category,” said Rick DeLuca, president, Merck Animal Health. “The extensive breadth and depth of our product portfolio enhances our

July 2, 2020

Merck Animal Health Completes Acquisition of Quantified Ag®

Broadens Livestock Digital Portfolio to Improve Animal Well-being Through Connected Technology Merck Animal Health, known as MSD Animal Health outside the United States and Canada, a division of Merck & Co., Inc., Kenilworth, N.J., USA (NYSE:MRK), today announced the completion of its acquisition of Quantified Ag ® , a leading data and analytics company that monitors cattle body temperature and movement in order to detect illness early. In April 2018, Merck Animal Health invested in Quantified Ag ® and partially funded their development work in data analytics in livestock. Specific terms of the agreement were not disclosed. Today’s announcement further positions Merck Animal Health as a global leader in animal health, broadening its portfolio in connected technology to improve cattle health outcomes by leveraging data and analytics for animal health and well-being. Quantified Ag ® , located in Lincoln, Nebraska, provides a pro-active system for cattle producers and feedlot

June 17, 2020

Merck Animal Health to Acquire U.S. Rights to SENTINEL® Brand of Combination Parasiticides for Companion Animals

Further Solidifies Merck Animal Health’s Position in the U.S. Companion Animal Category with Comprehensive, Continuous Parasite Protection Complements Merck Animal Health’s Broad Portfolio of Vaccines and Pharmaceuticals Merck Animal Health, known as MSD Animal Health outside the United States and Canada, a division of Merck & Co., Inc., Kenilworth, N.J., USA (NYSE:MRK), and Virbac (NYSE Euronext:VIRP) today announced that the companies have signed a definitive agreement under which Merck Animal Health would acquire the U.S. rights to SENTINEL® FLAVOR TABS® and SENTINEL® SPECTRUM® Chews in the Companion Animal category. Merck Animal Health will make a cash payment of approximately $400 million to acquire the SENTINEL branded products in the United States at closing of the acquisition. Comprehensive parasite protection is an essential part of canine overall health and well-being. The BRAVECTO® product line, which are our extended duration flea and tick protection products, and the

May 13, 2020

Merck Animal Health Completes Acquisition of Vaki to Further Broaden Its Leadership Position in Aquaculture to Advance Fish Health and Welfare

Merck Animal Health, a division of Merck & Co., Inc., Kenilworth, N.J., USA (NYSE:MRK), today announced the completion of its acquisition of Vaki, a leader in fish farming and wild fish conservation monitoring equipment and real-time video monitoring technology to advance fish health and welfare, from Pentair (NYSE:PNR), a leading global water treatment company. Today’s announcement further positions Merck Animal Health as a global leader in broadening its aquaculture portfolio by expanding into complementary fish farming and conservation areas to generate outcomes with precision farming and fish welfare solutions, which complement its existing portfolio of vaccines and pharmaceuticals. Vaki will be a leading brand under the Biomark business within Merck Animal Health, focused on a range of equipment, products and technology for fish counting and size estimation from freshwater to saltwater rearing, while collecting data and analytics for each stage of fish production. “Animal

December 17, 2019

BRAVECTO® PLUS (fluralaner and moxidectin topical solution) for Cats Receives Approval from US Food and Drug Administration

Merck Animal Health, a division of Merck & Co., Inc., Kenilworth, N.J., USA (NYSE: MRK), today announced the U.S. approval of BRAVECTO ® PLUS topical solution for cats by the U.S. Food and Drug Administration (FDA). BRAVECTO PLUS is an extended-duration, broad-spectrum combination (fluralaner and moxidectin) topical solution for cats, indicated for both external and internal parasite infestations: ticks and fleas, heartworm, intestinal roundworm and hookworm. This unique formula in BRAVECTO PLUS provides extended protection for up to two months with just one application, making it the only product on the market to protect against this combination of parasites at a longer duration. BRAVECTO PLUS is expected to be available in the coming months. “BRAVECTO PLUS addresses five of the top parasite concerns among veterinarians and cat owners, including ticks, fleas, heartworms, roundworms and hookworms,” said Christine Royal, DVM, director, Professional Services at Merck Animal Health.

November 15, 2019

Sure Petcare Launches SureFeed® Microchip Pet Feeder Connect

Sure Petcare, the pet technology specialist, today announced the launch of the SureFeed® Microchip Pet Feeder Connect, the next generation of the best-selling SureFeed Microchip Pet Feeder, which monitors the eating behavior of pets. The smart feeder monitors how much and when a pet eats, sending real-time updates directly to the pet owner’s phone. The new product also features integrated scales, which enable owners to provide accurate food portions to their pet at every meal. Feeding behavior is a key indicator of health for pets with a loss of appetite or change in feeding habits often being one of the first signs of illness. The SureFeed Microchip Pet Feeder Connect records the time and weight of food consumed by a pet each time they eat from the feeder, reporting it directly to the Sure Petcare app. Over time, this enables pet owners to build a comprehensive understanding of their pet’s unique feeding patterns, making it easier for them to spot changes in their pet’s health and

July 22, 2019

Merck Completes Acquisition of Antelliq Corporation to Become Leader in Emerging Digital Technology for Livestock and Companion Animals

Merck [NYSE:MRK], known as MSD outside the United States and Canada, today announced the completion of its acquisition of Antelliq Corporation from funds advised by BC Partners. Today’s announcement positions the company as a global leader in animal health digital tracking, traceability and monitoring technology and complements the existing portfolio of vaccines and pharmaceuticals. Antelliq will be an operating unit within Merck Animal Health. “The animal health industry is rapidly evolving with revolutionary digital solutions to manage the health and well-being of livestock and companion animals with animal identification, animal monitoring and smart data management as critical components of this technology,” said Rick DeLuca, president, Merck Animal Health. “Through our commitment to the Science of Healthier Animals®, we are dedicated to advancing the health and well-being of animals and the people who take care of them. We are excited to take this step forward with Antelliq and

April 1, 2019

Merck to Acquire Privately Held Antelliq Group

Merck [NYSE:MRK], known as MSD outside the United States and Canada, and privately held Antelliq Group today announced that the companies have signed a definitive agreement under which Merck will acquire Antelliq from funds advised by BC Partners. Antelliq will be a wholly owned and separately operated subsidiary within the Merck Animal Health Division. Merck will make a cash payment of approximately 2.1 billion euros to acquire all outstanding shares of Antelliq and will assume Antelliq’s debt of 1.15 billion euros, which it intends to repay shortly after the closing of the acquisition. Antelliq is a leader in digital animal identification, traceability and monitoring solutions, the fastest growing part of the animal health industry, with 360 million euros in sales in the 12-month period ending Sept. 30, 2018. These solutions help veterinarians, farmers and pet owners gather critical data to improve management, health and well-being of livestock and pets. The increasing use of

December 14, 2018

First-of-its-Kind Study Reveals Concern about the Future of the Veterinary Profession

Results Presented at 2018 Veterinary Meeting & Expo (VMX) Merck Animal Health (known as MSD Animal Health outside the United States and Canada) today announced the results of a large, well-controlled study with veterinarians designed to definitively quantify the prevalence of mental illness and stress in the veterinary profession and compare the findings to previous studies and the general U.S. population. Conducted in collaboration with the American Veterinary Medical Association (AVMA) and Merck Animal Health, the study found veterinarians age 45 and younger are more likely to experience serious psychological distress and only 27 percent of them would endorse the profession to a friend or family member. “This survey is unique in that, for the first time, a nationally representative sample of veterinarians in the U.S. were asked about their wellbeing, which is a broader measure of happiness and life satisfaction than mental health alone,” said study investigator Linda Lord,

February 6, 2018

Merck Animal Health Extends Commitment to Fighting Rabies in the World’s Most At-Risk Regions

Africa and India Still Bear Highest Burden of Annual Rabies Deaths Today marks the midway milestone for World Rabies Day, when the Global Alliance for Rabies Control, together with health organizations from around the world, set a goal of eliminating human rabies transmitted by dogs by 2030. Merck Animal Health (known as MSD Animal Health outside the United States and Canada) is pleased to announce our continued support in the fight against rabies through the donation of NOBIVAC® Rabies vaccine and other resources to the Afya Serengeti Project and Mission Rabies, organizations working to eliminate this disease in the world’s most at-risk regions. Rabies, a neglected disease of vulnerable populations, is nearly 100 percent fatal but also nearly 100 percent preventable through canine vaccination. Africa and India still bear the highest burden of total annual rabies deaths. i Countries with the highest fatalities from rabies are India, Democratic Republic of the Congo, Ethiopia, China

September 28, 2017

MSD Animal Health to Purchase Manufacturing Facility in Krems, Austria

European Facility Will Boost Global Vaccine Production Capacity MSD Animal Health, known as Merck Animal Health in the United States and Canada, today announced plans to purchase a new manufacturing facility in Krems an der Donau, Austria with the intention to expand its global vaccine manufacturing capacity. The facility, currently owned by Shire plc., was built in 2002 and will add to the company’s impressive global manufacturing capabilities. “This new manufacturing site is ideally located in central Europe. It provides MSD Animal Health additional manufacturing resources and advanced technology platforms to meet the growing demand for our vaccine products that prevent disease and keep animals healthy while positioning us for strong long-term growth,” stated Joseph Morrissey, senior vice president, operations, MSD Animal Health. “We are excited to expand our footprint to Krems,” stated Dr. Hans-Günther Dittrich, vice president, Europe, Russia, North Africa, Middle East region.

August 7, 2017

Merck Animal Health Completes Acquisition of Vallée S.A.

Broadening Our Comprehensive Portfolio of Animal Health Products for Brazilian Market Merck Animal Health (known as MSD Animal Health outside the United States and Canada) today announced it has successfully acquired a controlling interest in Vallée S.A., a leading privately-held producer of animal health products in Brazil. “The combined strength of the two companies under the umbrella of MSD Animal Health will provide customers with a more comprehensive portfolio of products for livestock animals,” said Rick DeLuca, president, Merck Animal Health. “We will continue to seek opportunities like these that complement our business and bring value to our customers.” About Merck Animal Health For over a century, Merck Animal Health has been a global health care leader working to help the world be well. Merck Animal Health, known as MSD outside the United States and Canada, is the global animal health business unit of Merck Animal Health. Through its commitment to the Science of Healthier

March 22, 2017

Merck Animal Health Announces USDA Approval of Innovative Canine Flu Bivalent Vaccine

First Vaccine to Offer Protection Against Both Strains of Canine Influenza Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, today announced that the U.S. Department of Agriculture has approved a license for Nobivac® Canine Flu Bivalent vaccine – the first vaccine to aid in the control of disease associated with both canine influenza virus (CIV) H3N2 and canine influenza virus H3N8. “Merck Animal Health has a rich history of vaccine development supported by a wealth of expertise, as well as a deep commitment to bringing innovative products to market that truly impact the health and well-being of animals,” said KJ Varma, BVSc, Ph.D., senior vice president, R&D, Merck Animal Health. “Our new bivalent canine influenza vaccine will simplify protection against this disease and is a tremendous example of our ongoing pursuit of the science of healthier animals and our dedication to providing veterinarians with new medicines and vaccines to advance

October 7, 2016

Merck Animal Health Receives FDA Approval of BRAVECTO® (fluralaner topical solution) for Cats and Dogs

Topical Treatment for Fleas and Ticks Effective for up to 12 Weeks Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, today announced the U.S. Food and Drug Administration’s approval of BRAVECTO® (fluralaner topical solution) for both cats and dogs, a topical treatment for fleas and ticks effective for up to 12 weeks1,2 following a single dose. “The approval of a second BRAVECTO product builds on the strong foundation and body of scientific evidence that we have established with our chewable tablet for dogs, our oral flea and tick product,” said KJ Varma, senior vice president, research and development, Merck Animal Health. “With BRAVECTO Topical, we have expanded our portfolio in the fight against parasites, as well as provided cats flea and tick protection that delivers immediate and persistent killing activity for 12 weeks – another first in the industry.” BRAVECTO Topical is available in a convenient, single-dose spot-on, and is applied

July 21, 2016

Merck Animal Health Announces Agreement to Acquire Controlling Interest In Brazilian Animal Health Company Vallée S.A.

Manufacturer Offers Substantial Portfolio of Animal Vaccines in Latin America Merck Animal Health (known as MSD Animal Health outside the United States and Canada) today announced it has executed an agreement to acquire a controlling interest in Vallée S.A., a leading privately-held producer of animal health products in Brazil. Vallée has an extensive portfolio of more than 100 products spanning parasiticides, anti-infectives and vaccines. The company’s portfolio includes products for livestock, horses, and companion animals. Vallée was founded with the mission of producing a Foot and Mouth Disease (FMD) vaccine for Brazil and has expanded significantly, with distribution centers in Brazil and operations in Paraguay, Venezuela, Mexico and Bolivia. “Merck Animal Health has a broad portfolio of products to protect against some of the most important pathogens affecting livestock,” said Rick DeLuca, president, Merck Animal Health. “We are pleased to complement our portfolio with products

July 1, 2016

MSD Animal Health Receives Marketing Approval from European Medicines Agency for BRAVECTO™ (fluralaner) Spot-On Solution for Cats and Dogs

Spot-On Treatment for Fleas and Ticks Effective For 12 Weeks MSD Animal Health (known as Merck Animal Health in the United States and Canada) today announced that, following a positive opinion from the Committee for Medicinal Products for Veterinary Use (CVMP), the European Medicine Agency has granted a marketing authorization for the veterinary medicinal product BRAVECTO™ (fluralaner) Spot-On Solution for both cats and dogs, a Spot-On treatment for fleas and ticks effective for 12 weeks following a single dose. BRAVECTO Spot-On, a systemic insecticide and acaricide, is indicated for the treatment of tick and flea infestations on cats and dogs and provides immediate and persistent flea and tick killing activity for 12 weeks. BRAVECTO Spot-On is applied topically using the new “Twist’n’Use”™ pipette design for ease of application. Detailed conditions of the product will be described in the summary of product characteristics (SPC) which will be published in the European public

May 24, 2016

Merck Animal Health to Acquire Worldwide Rights to Whisper® Veterinary Stethoscope System

Non-Invasive Device Helps Diagnose Bovine Respiratory Disease Merck Animal Health (known as MSD Animal Health outside the United States and Canada) today announced plans to acquire worldwide rights for the Whisper ® Veterinary Stethoscope System from Minnesota-based Geissler Companies. The Whisper Veterinary Stethoscope System is a Bovine Respiratory Disease (BRD) detection system which is used to determine the severity of an animal’s lung condition so that the appropriate treatment regimen can be started to protect the health of the animal. Bovine Respiratory Disease is the most common disease affecting cattle in North America.1 This complex, multi-factorial infection affects the upper and lower respiratory tracts and can often be fatal, causing billions of dollars in economic losses for farmers. Identifying the cause of the disease and appropriate treatment pathways is vital to maintain an infected herd. “We are pleased to add the Whisper Veterinary Stethoscope System to our

April 19, 2016

MSD Animal Health Receives Positive Final Opinion from European Medicines Agency for BRAVECTO™ (fluralaner) Spot-On for Cats and Dogs

Only Spot-On Treatment for Fleas and Ticks Effective For 12 Weeks MSD Animal Health (known as Merck Animal Health in the United States and Canada) today announced that the Committee for Medicinal Products for Veterinary Use (CVMP) of the European Medicines Agency has adopted a positive final opinion, recommending the granting of a marketing authorization for the veterinary medicinal product BRAVECTO™ (fluralaner) Spot-On for both cats and dogs. In 2014, BRAVECTO was launched as a chew for dogs providing protection with its active ingredient, fluralaner, against fleas and ticks for up to 12 weeks with a single treatment. BRAVECTO Spot-On provides 12 weeks of flea and tick protection for both cats and dogs with the same active ingredient as BRAVECTO chew. More than 13 million doses of BRAVECTO have been dispensed in 60 countries since its introduction. BRAVECTO Spot-On will be the first product to provide immediate and persistent systemic flea and tick protection for cats and gives

March 22, 2016

New Pet Diabetes Tracker from Merck Animal Health Helps Owners of Diabetic Pets Manage the Disease

Pet owners can monitor everything from food consumption to blood glucose MADISON, N.J. – Merck Animal Health (known as MSD Animal Health outside the United States and Canada) today announced the launch of the Pet Diabetes Tracker, a free app that helps pet owners manage their pet’s diabetes on their smartphone or tablet. Diabetes is a serious condition that can be easily and effectively managed if pet owners know what to look for, and work with their veterinarian on a health plan for their dog or cat. The prevalence of diabetes mellitus in dogs and cats ranges from at least one in 100 1 to one in 500 2 . The number of dogs diagnosed with the condition has tripled during the past 30 years 3 . Dogs receiving the proper treatment, however, have the same lifespan as a non-diabetic dog of the same age and sex 3 . A diabetic cat can also have a happy and healthy life with treatment, an appropriate diet and regular healthcare routine. The Pet Diabetes Tracker helps the pet owner to do

February 11, 2016

Merck Animal Health Pioneers H3N2 Canine Influenza Vaccine

Innovative Addition Further Strengthens CIV Product Line Madison, N.J. - In response to the H3N2 canine influenza (CIV) outbreaks that impacted dogs in 241 states, Merck Animal Health (known as MSD Animal Health outside the United States and Canada) today announced the U.S. Department of Agriculture (USDA) has issued a conditional product license for a vaccine to protect against this newly identified strain of CIV. Canine Influenza Vaccine H3N2 will be available to U.S. veterinarians beginning Monday, November 23. “We have a long history of bringing innovative products to the market that truly impact the health and well-being of animals, and this vaccine is another example of our deep commitment to animal health and veterinarians,” said KJ Varma, BVSc, Ph.D., Diplomate ACVCP, Senior Vice President Global R&D, Merck Animal Health. “Building on our legacy of vaccine expertise, we are excited to be able to offer a cutting-edge product that will protect dogs against this virulent

November 20, 2015

Merck Animal Health to Acquire Harrisvaccines

Acquisition Expands and Complements Merck Animal Health’s Strong Vaccine Portfolio MADISON, N.J. – Merck Animal Health (known as MSD Animal Health outside the United States and Canada) and Harrisvaccines, Inc., today announced the companies have entered into an agreement under which Merck Animal Health will acquire Harrisvaccines, a privately-held company that develops, manufactures and sells vaccines for food production and companion animals. “As a leader in biologics, Merck Animal Health has built a robust portfolio of vaccines across all animal species,” stated Rick DeLuca, president, Merck Animal Health. “Combining Harrisvaccines’ R&D and portfolio of products with our strong capabilities and global reach will enable us to address even more devastating diseases that are impacting production animals and reinforce our commitment to the science of healthier animals.” Harrisvaccines offers innovative technology and an important portfolio of vaccines, with a focus on production

November 12, 2015

Merck Animal Health Provides Update on Zilmax Five-Step Plan, Announces Next Steps

Extensive review and analysis of research data completed Final stage to focus on planned in-field use studies Best Management Practices and Certification Program adopted FDA approval of updates to Zilmax label, including new feed delivery method Merck Animal Health (known outside the United States and Canada as MSD Animal Health) is pleased to announce significant progress in the implementation of its Zilmax Five-Step Plan. With insights from the company’s advisory board, an extensive assessment and analysis of existing, as well as new product data, was conducted. Additionally, Merck Animal Health obtained the input of industry experts, business partners and customers about the product and its use. The totality of the comprehensive review supported that Zilmax ® (zilpaterol hydrochloride) is safe when used according to the product label and in conjunction with sound animal husbandry practices. The research results and industry data showed that cattle weights, and thus feed consumption

November 5, 2014

Merck Animal Health Announces FDA Approval of BRAVECTO™ (fluralaner)

First Chewable Tablet for Dogs Effective for 12 Weeks* Against Fleas and Ticks Merck Animal Health (known as MSD Animal Health outside the United States and Canada) today announced the U.S. Food and Drug Administration’s approval of BRAVECTO™ (fluralaner) chewable tablets for dogs (112.5 mg, 250 mg, 500 mg, 1000 mg, 1400 mg). BRAVECTO is the first and only treatment that has been shown to quickly and effectively kill fleas and multiple tick species for 12 weeks in a single dose. BRAVECTO also is effective for eight weeks against Amblyomma americanum ticks. “BRAVECTO is a breakthrough innovation that offers pet owners and veterinarians something that no other product does – the longest-lasting oral flea and tick prevention currently available,” said KJ Varma, Senior Vice President, Research and Development, Merck Animal Health. “The approval of BRAVECTO is truly a reflection of our 70-year history of innovation, research and commitment to helping shape the future of animal

May 20, 2014

Study Results Show ACTIVYL® by Merck Animal Health Outperforms FRONTLINE® Plus

Eliminates More Than 99 Percent of Fleas: More Flea-Free Pets and Fewer Fleas in the Home Merck Animal Health today released the results of a head-to-head research study that showed ACTIVYL® (indoxacarb) was more effective than FRONTLINE® Plus (fipronil [s]-methoprene) in controlling flea populations on pets.1 ACTIVYL eliminated more than 99 percent of fleas on pets after two monthly applications versus a 54.8 percent reduction achieved by FRONTLINE Plus (p≤ 0.0079). 1 At the end of the two-month study, nearly five times more pets treated with ACTIVYL were flea free, and ACTIVYL users found significantly fewer fleas in their homes. 1 “The pets in this study had the largest natural flea burdens the investigators had ever seen and were under continual reinfestation pressure. The data clearly show that ACTIVYL was still able to effectively control the flea infestations,” said Kathleen Heaney, D.V.M., director of technical services for Merck Animal Health. “Following monthly

February 26, 2014

MSD Animal Health Receives Marketing Authorization from European Commission for BRAVECTO™ (fluralaner)

First Chewable Tablet Approved for Fleas and Ticks in Dogs Effective for 12 Weeks (8 Weeks for Rhipicephalus sanguineus Ticks) MSD Animal Health, known as Merck Animal Health in the United States and Canada, announced today that following a positive opinion from the Committee for Medicinal Products for Veterinary Use (CVMP), the European Commission has granted marketing authorization for the veterinary medicinal product BRAVECTO™ (fluralaner) chewable tablets for dogs (112.5 mg, 250 mg, 500 mg, 1000 mg, 1400 mg). This is the first and only treatment that has been shown to quickly and effectively kill fleas and ticks for up to 12 weeks in a single dose.* “BRAVECTO provides a powerful new weapon in the fight against these dangerous parasites,” said KJ Varma, senior vice president, Research & Development, MSD Animal Health. “We are incredibly proud to bring this new innovative chewable tablet to dog owners, which we could not have done without the partnership of the clinical

February 17, 2014

MSD Animal Health Receives Positive Opinion from European Medicines Agency for BRAVECTO™ (fluralaner)

New Chewable Tablet Treatment for Fleas and Ticks in Dogs – Effective For 12 Weeks (8 weeks for Rhipicephalus sanguineus ticks) MSD Animal Health (known as Merck Animal Health in the United States and Canada) today announced that the Committee for Medicinal Products for Veterinary Use (CVMP) of the European Medicines Agency has adopted a positive opinion, recommending the granting of a marketing authorization for the veterinary medicinal product BRAVECTO™ (fluralaner) chewable tablets for dogs (112.5 mg, 250 mg, 500 mg, 1000 mg, 1400 mg). The active substance of BRAVECTO, fluralaner, a new ectoparasiticide belonging to the isoxazoline group, is systemically active against fleas and ticks. The benefits of BRAVECTO are its efficacy in the treatment of flea and tick infestations in dogs. The most common side effects are mild and transient gastrointestinal effects. If adopted, approved indication: BRAVECTO will be indicated for the treatment of tick and flea infestation on dogs. It is a

December 17, 2013

Merck Animal Health Launches Global Awareness Campaign

“A Healthy Pet = A Happy Family” Encourages Pet Screening and Treatment Merck Animal Health has launched a global awareness campaign to support Pet Diabetes Month™ this November. The “A Healthy Pet = A Happy Family” campaign highlights that just like humans, dogs and cats can also suffer from diabetes – a relevant message as November is also American Diabetes Month. The campaign is designed to raise awareness of the signs of the condition among pet owners, in an effort to encourage them to visit their veterinarians to have their pets screened and treated. “Pet owners should be aware of the possible warning signs of pet diabetes and see their veterinarians for a definitive diagnosis,” said Madeleine Stahl, DVM. “Considering the fact that pet diabetes can be effectively managed, lack of owner awareness may be the biggest risk factor associated with this condition.”

November 15, 2013

Merck Animal Health’s HomeAgain® Announces Finalists for Hero of the Year Award; Voting Begins

HomeAgain ® Pet Recovery Service, a division of Merck Animal Health, today announced the five finalists for the HomeAgain Hero of the Year Award. Chosen by an esteemed panel of judges from the animal welfare community, each finalist was identified as having outstanding dedication to supporting the health and well-being of companion animals. “We received hundreds of nominations detailing countless ways people are contributing to and making a difference in animal well-being,” said Linda Block, marketing director for HomeAgain. “These stories are a true testament to the amazing character of the people that make up the companion animal community. We are proud to be able to recognize these unsung heroes.” The award winner will be determined by a public vote, which will run through October 21, 2013. Everyone is encouraged to read about the finalists and vote for their favorite on HomeAgainHeroes.com , as well as share these truly remarkable stories with friends, family and colleagues. About

September 30, 2013

Merck Animal Health Proudly Supports Vaccination Programs Targeted at Reducing Disease in Domestic Pets

More Than One Million Doses of Rabies Vaccine Donated In recognition of World Rabies Day, and in an effort to reduce the number of people dying of the disease, Merck Animal Health (known as MSD Animal Health outside the USA and Canada) is proud to support canine rabies vaccination programs in some of the most at-risk regions in the world. To date, more than one million doses of veterinary rabies vaccine have been donated in the effort to eliminate the risk to human health in these regions. Rabies is a debilitating and deadly problem that affects people and their pets all over the world. According to the World Health Organization, more than 55,000 people die of rabies every year, mostly in Asia and Africa. For this reason, Merck Animal Health has donated up to 300,000 doses of lifesaving veterinary rabies vaccine to those regions this year alone. The program runs in more than 20 developed countries, where participating veterinarians and pet owners who chose Merck Animal Health’s

September 28, 2013

Merck Animal Health Strengthens Commitment to Five Steps to Responsible Beef

At Merck Animal Health, the health and well-being of animals is our first and foremost priority. We also take very seriously our commitment to providing safe, effective products that are developed based on comprehensive research, rigorous testing and sound science. We believe in the science that supports Zilmax and are confident in its safety and performance. Reinforcing this science and data-based approach, Merck Animal Health has announced it has strengthened its commitment to its Five-Step Approach to Ensuring Responsible Beef. As previously announced, Merck Animal Health, in conjunction with independent experts, will conduct a scientific audit, which will monitor the process of feeding of Zilmax, and will follow identified cattle from the feedyard to the packing plant to determine potential causes of lameness and other mobility issues during feeding, transportation, offloading and staging at the processing facility. We also will do a thorough review of potential compounding

August 16, 2013

Best Practices, Performance Technologies Presented at ADSA-ASAS Joint Annual Meeting

Opportunities for Stronger Economic Returns, Greater Environmental Sustainability The beef industry faces the challenge of producing enough affordable beef to meet the nutritional requirements of an ever-growing global population. This is being accomplished through best practices that positively impact both the environment and economics. Jude Capper, Ph.D, Affiliate at Montana State University and Adjunct Professor at Washington State University, presented three posters highlighting best practices at the joint annual meeting of the American Dairy Science Association (ADSA) and the American Society of Animal Science (ASAS) earlier this month. The posters are based on three different studies and look at parasite control, calving rates and use of technologies. They highlighted key best practices within U.S. beef production that help farmers achieve optimum productivity to balance environmental responsibility and economic viability. Dr. Capper’s first poster focused on

July 23, 2013

Merck Animal Health Releases Second Module in Dairy Care365TM Training Series – Milk Parlor Handling

In today’s challenging economy, it’s vital that dairy producers make the most of every husbandry practice, including low-stress handling of their herd. Effective handling results in increased milk production, improved animal well-being and safer working conditions for employees. Merck Animal Health’s new “Moving Cows to the Milking Parlor” training, the second module in the company’s Dairy Care365 training series developed in partnership with the University of Minnesota College of Veterinary Medicine, highlights the importance of this management practice and the value it can bring to the operation. “Applying good dairy stockmanship techniques can make a significant difference – fewer injuries to livestock and their handlers, improved cattle responsiveness, and increased feed consumption that equates to healthier and more productive animals – all of which result in a more successful, profitable operation,” says Mike Bolton, D.V.M., Merck Animal Health technical services manager. “The

June 24, 2013

HomeAgain® Launches Program to Recognize Companion Animal Heroes

HomeAgain ® Pet Recovery Service today announced a nationwide search for companion animal “heroes” and is reaching out to communities across the country to help find the HomeAgain Hero of the Year. The newly established program will recognize individuals who dedicate themselves to supporting the health and well-being of companion animals, whether through their everyday work or volunteer efforts. In commemoration of the heroes’ efforts, HomeAgain will make a $10,000 donation in the name of the HomeAgain Hero of the Year award winner, as well as donations in the name of each of the four finalists to Petfinder Foundation, Winn Feline Foundation, Assistance Dogs International or Morris Animal Foundation. “Given the focus of our business, we feel it’s important to recognize and honor individuals who make significant contributions to help ensure the welfare of animals,” said Gary MacPhee, director and general manager of HomeAgain. “We are proud to establish an award that will spotlight the

June 5, 2013

Dr. Mike Apley Recognized by Peers for Outstanding Industry Support

Recognized for his leadership in beef cattle health and food safety, Kansas State University professor Mike Apley, D.V.M., Ph.D., D.A.C.V.C.P., recently received the 2013 Outstanding Service Award from the Academy of Veterinary Consultants (AVC). Dr. Apley was honored for dedicating his career to improving animal health and veterinary medicine by sharing his insights and expertise on antibiotic use in livestock. Sponsored by Merck Animal Health, the annual award recognizes an AVC member who has made exceptional contributions to the organization, as well as the beef cattle and veterinary medical professions. In support of the company’s long-standing commitment to honoring those who have made an indelible mark on the industry and supporting future leaders, Merck Animal Health also made a donation to the AVC Foundation in Dr. Apley’s honor. “There is a wealth of experience, knowledge and expertise among the membership that is willingly shared with others,” said Dr. Apley. “To be selected

May 3, 2013

Merck Animal Health Introduces Fresh, New Look for Safe-Guard® Equi-bits® Package

Merck Animal Health today introduced a new creative approach to its packaging of Safe-Guard ® (fenbendazole) Equi-bits ® equine dewormer. A clear, apple-shaped window has been added to the front of all Equi-bits packaging; putting a greater emphasis on its unique apple flavoring, which is a popular feature for many horse owners. Equi-bits, an easy to administer alfalfa-based pellet, is a solid choice for any deworming plan. The top dress pellets allow for easy, effective deworming, especially for those hard-to-catch, hard-to-deworm horses. Equi-bits help control large strongyles, small strongyles, pinworms, and ascarids, and is safe for foals and pregnant mares. “Effective deworming is vital to the health and well-being of every horse, and deworming is made easier when you can choose the delivery method that works best for you and your horse,” said Stacy Basinger, Equine Retail Marketing Manager, Merck Animal Health. “Equi-bits offers horse owners an effective top dress option with

April 30, 2013

Merck Animal Health Announces Vetsulin® Now Available to the U.S. Veterinary Market

Merck Animal Health today announced that Vetsulin ® (porcine insulin zinc suspension), the only FDA-approved insulin for use in both dogs and cats is now available to veterinarians throughout the United States. The prevalence of diabetes mellitus in dogs and cats ranges from one in 100 1 to one in 500, 2 and the number of dogs diagnosed with the disease has tripled during the past 30 years. 3 Today, along with proper diet and exercise, Vetsulin plays an important role in successfully managing diabetes in both dogs and cats. “We are pleased that Vetsulin is again available in the U.S. market; offering our customers the same product benefits that veterinarians worldwide have relied on for the past 20 years,” said Christopher Pappas, D.V.M., Director, Technical Services, Merck Animal Health. “At Merck Animal Health, we are committed to providing our full support to veterinarians as they manage the health of dogs and cats living with diabetes.” While only 50 percent of dogs used to

April 29, 2013

HOMEAGAIN® Pet Recovery Service Awarded Exclusive PetfinderTM Seal of Approval

Among First to Receive Recognition from Trusted Animal Welfare Advocate HomeAgain®Pet Recovery Service was recently honored with the Seal of Approval by Petfinder, the largest online, searchable database of animals that need permanent homes. HomeAgain is one of only four companies to receive this distinction, which recognizes organizations with a strong commitment to making a positive impact on the welfare of animals. “We are honored by the recognition and are proud to partner with such a worthy organization,” said Gary MacPhee, director and general manager of HomeAgain. “PetFinder is well known for its mission to find homes for animals and reunite pets and owners, and we will continue to work with this group to help ensure the safety and welfare of animals throughout the country.” One in three pets will go missing in their lifetime and, without proper identification, 90 percent of these pets will not return home. A microchip is the only form of pet identification that is permanent,

April 19, 2013

Cattle Production Veterinarian Hall of Fame Nominees Announced

Six legendary cattle veterinarians have been nominated for the 2013 Cattle Production Veterinarian Hall of Fame, which celebrates the rich traditions of production veterinary medicine by honoring exceptional individuals who have made lasting contributions to the veterinary profession. From the development of herd health protocols and management strategies to maintaining leadership roles in teaching and research, these nominees have helped shape the industry throughout their distinguished careers. The Cattle Production Veterinarian Hall of Fame is sponsored by the American Association of Bovine Practitioners (AABP), the Academy of Veterinary Consultants (AVC),Bovine Veterinarian,Merck Animal Health and Osborn Barr, an agricultural marketing and communications company. “Selected by their peers, each of the nominees represents a legacy of excellence, dedication and accomplishment that make them truly worthy of Hall of Fame recognition,” says Mark Spire, D.V.M., technical services manager

April 17, 2013

Todd Bilby, Ph.D., Joins Merck Animal Health’s Dairy Technical Services Team

Todd Bilby, Ph.D., has joined Merck Animal Health’s Dairy Technical Services team, which offers a broad range of support services for dairy producers and veterinarians, including animal health protocols, diagnostics, product support and employee training. “Dr. Bilby’s expertise in reproduction, cow comfort and transition management will be a great asset to our customers,” says Scott Nordstrom, D.V.M., director of dairy technical services. “He’s an accomplished author and speaker, with a tremendous understanding of research design and extensive experience in dairy record analysis, all of which will benefit dairy producers and veterinarians.” Prior to joining Merck Animal Health, Dr. Bilby was an associate professor and dairy extension specialist at Texas A&M AgriLife and an assistant professor at the University of Arizona. He has authored or co-authored more than 65 scientific peer-reviewed publications and abstracts, more than 100 symposium proceedings and publications, and more than

April 3, 2013

Merck Animal Health Launches Protectotype™ - An Innovative Vaccination Program to Increase Infectious Bronchitis Protection in Poultry

Infectious bronchitis (IB) is a significant challenge for the poultry industry given the speed and frequency with which the disease evolves and spreads, as well as its negative impact on bird growth and egg production. Protectotype ™ , a novel poultry vaccination program, offers a proven approach to managing multiple strains of IB in broiler and layer flocks, a critical health challenge for U.S. poultry producers. The Protectotype system, which is widely used in Europe, focuses on maximizing IB protection through the combination of individual vaccines. “Research results have shown that by using two vaccines, producers can achieve a broader spectrum of IB protection,” says Charles Broussard, D.V.M, MAM, Merck Animal Health. “More specifically, when a bird receives two IB vaccines, it can gain protection to three or more IB serotypes – the two known IB serotypes and newly adapted IB serotypes for which there is no existing vaccine[1].” The resulting cross protection helps ensure

January 28, 2013

Animal Health

Forward-looking statement of Merck & Co., Inc., Rahway, N.J., USA

You are leaving Merck.com

Welcome to Merck.com